Contract Development Services

Delivering a Wealth of Expertise

February 02, 2021

Outsourcing partners can provide a multitude of advantages in the development of drug delivery solutions, including those designed for targeted patient populations.

Overcoming Biologic Drug Formulation Hurdles

January 03, 2021

The right partner can help companies overcome key formulation challenges for biologic drugs.

Unique Molecules Push Formulation Boundaries

October 03, 2020

More complex and challenging compounds require a more tailored approach to formulation strategies.

Build CMO Relationships with Effective Management Practices

August 01, 2020

Contract service providers offer vital services to bio/pharma companies of all sizes. Establishing an effective working relationship and managing operations are key to avoiding compliance issues.

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

July 21, 2020

Catalent has unveiled plans to invest in a European center of excellence for clinical biologics formulation development and drug product fill/finish services at its facility in Limoges, France.

Vetter Expands Fill/Finish Capacity with Acquisition of New Site in Austria

July 08, 2020

The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.

Lonza Announces Additional Investments in Global Particle Engineering Services

July 06, 2020

Lonza is making additional investments in its global particle engineering network for expanded capacity and specialized capabilities.

Demand for Custom Dosage Forms Fuels Innovation

July 02, 2020

Demand for custom drug delivery solutions is increasing and bringing forth an exciting period of valuable, innovative development opportunities.

Contractors Balance Increased Demand During COVID-19

July 02, 2020

The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.

AMRI Announces Increased Production of Hydroxychloroquine Sulfate for COVID-19 Treatment

May 04, 2020

FDA approved hydroxychloroquine sulfate for emergency use as a treatment for some hospitalized patients with COVID-19.